2022
Treatment exposure-based risk-stratification for care of survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.
Dinan M, Stratton K, Leisenring W, Yasui Y, Chow E, Moskowitz C, Yeh J, Noyd D, Armstrong G, Oeffinger K. Treatment exposure-based risk-stratification for care of survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Journal Of Clinical Oncology 2022, 40: 10056-10056. DOI: 10.1200/jco.2022.40.16_suppl.10056.Peer-Reviewed Original ResearchChildhood Cancer Survivor StudyHigh-risk groupHigh-risk survivorsCancer Survivor StudyRisk groupsGrade 3Hazard ratioRisk survivorsAge 20Cumulative incidenceChronic conditionsSurvivor StudyChildhood cancerAge 35Treatment exposureLow-risk survivorsFive-year survivorsHigh-risk patientsRisk stratification algorithmConfidence intervalsProportional hazards modelLong-term surveillanceCare of survivorsLate mortalityPrimary endpointEvaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma
Miller SM, Wilson LE, Greiner MA, Pritchard JE, Zhang T, Kaye DR, Cohen HJ, Becher RD, Maerz LL, Dinan MA. Evaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma. Journal Of Geriatric Oncology 2022, 13: 635-643. PMID: 34996724, PMCID: PMC9232862, DOI: 10.1016/j.jgo.2021.12.012.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaNon-cancer controlsRenal cell carcinomaMRCC diagnosisMild cognitive impairmentCell carcinomaRisk factorsCognitive impairmentOlder adultsProportional hazards modelNew cancer treatmentsCohort entryOlder patientsSurgical therapyMAIN OUTCOMEExclusion criteriaAgent useDisease processHazards modelPatientsMedicare datasetCancer treatmentDiagnosisDementiaCarcinoma
2021
Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents.
Spees L, Dinan M, Jackson B, Baggett C, Wilson L, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Wheeler S. Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents. Journal Of Clinical Oncology 2021, 39: 116-116. DOI: 10.1200/jco.2020.39.28_suppl.116.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anti-cancer agentsPatients' clinical characteristicsProvider-level factorsCause mortalityRenal cell carcinomaClinical characteristicsHazard ratioMetastatic diagnosisCell carcinomaState cancer registry dataCox proportional hazards modelProvider-level predictorsLower overall survivalOral anticancer agentsCancer registry dataReal-world populationProportional hazards modelSkilled nursing facilitiesProvider Enumeration SystemAnti-cancer agentsIndex dateOverall survivalPatient demographicsBlack patients
2014
Extent of Surgery for Papillary Thyroid Cancer Is Not Associated With Survival
Adam MA, Pura J, Gu L, Dinan MA, Tyler DS, Reed SD, Scheri R, Roman SA, Sosa JA. Extent of Surgery for Papillary Thyroid Cancer Is Not Associated With Survival. Annals Of Surgery 2014, 260: 601-607. PMID: 25203876, PMCID: PMC4532384, DOI: 10.1097/sla.0000000000000925.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancerExtent of surgeryTotal thyroidectomyOverall survivalTumor sizeDistant metastasisThyroid cancerSurvival advantagePTC tumorsRadioactive iodine treatmentLarge contemporary cohortOverall survival advantageUnderwent total thyroidectomyProportional hazards modelPresence of nodalMultivariable adjustmentAdult patientsClinical factorsContemporary cohortMultifocal diseaseAbsolute indicationMale sexTumors 1.0Black racePTC patients